NCT04145856View on ClinicalTrials.gov

Combination of Alverine-simeticone and i3.1 Probiotic in IBS-D and IBS-M in Mexico

PHASE4CompletedINTERVENTIONAL
Enrollment

55

Participants

Timeline

Start Date

September 3, 2018

Primary Completion Date

May 2, 2019

Study Completion Date

August 27, 2019

Conditions
Irritable Bowel Syndrome
Interventions
DIETARY_SUPPLEMENT

I31 probiotic

I31 probiotic formula (dietary supplement), consisting of 3 billion cfus of strains P. acidilactici CECT7483, L.plantarum CECT7484 and L.plantarum CECT7485, once daily (u.i.d)

COMBINATION_PRODUCT

I31 probiotic combined to Alverine/Simethicone

"* I31 probiotic formula (dietary supplement), consisting of 3 billion cfus of strains P. acidilactici CECT7483, L.plantarum CECT7484 and L.plantarum CECT7485, once daily (u.i.d)~* Antispasmodic/antifoam drug, consisting of Alverine Citrate 60 mg and Simethicone 300 mg, thrice daily (t.i.d)"

OTHER

Placebo

Placebo treatment (maltodextrin), once daily (u.i.d)

Trial Locations (1)

07760

Hospital Juarez de Mexico, Mexico City

All Listed Sponsors
lead

Hospital Juarez de Mexico

OTHER_GOV

NCT04145856 - Combination of Alverine-simeticone and i3.1 Probiotic in IBS-D and IBS-M in Mexico | Biotech Hunter | Biotech Hunter